ArticleJournal of medical biochemistry2026
Dynamic monitoring of cognitive impairment and prognostic recurrence risk in patients with stroke by serum HDAC3 and FOXO1: A potential diagnostic approach.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the clinical value of dynamically monitoring serum histone deacetylase 3 (HDAC3) and forkhead box protein O1 (FOXO1) levels in evaluating cognitive impairment (CI) in cerebral stroke (CS) patients, to enable early identification of high-risk individuals and guide targeted interventions. Methods: This study included 120 CS patients admitted from March, 2023 to March, 2024, with their serum HDAC3 and FOXO1 levels examined upon admission (T0) and at 2 (T1) and 24 hours (T2) following treatment. Differences in biomarker levels (CI group vs. non-CI group) were analyzed, and the predictive value of HDAC3 and FOXO1 for CI was determined. In addition, patients were followed up for 1 year prognosis, and the predictive effect of HDAC3 and FOXO1 on the prognostic recurrence risk of CS was analyzed. Results: CI occurred in 46 cases. HDAC3 expression was markedly increased in CI cases versus non-CI patients at T0, T1, and T2, whereas FOXO1 differed significantly only at T1 and T2 (P< 0.05). HDAC3 and FOXO1 showed maximal predictive value for CI at the T2 timepoint. Similarly, the increase of HDAC3 and FOXO1 was also related to the risk of prognosis recurrence of CS patients. The sensitivity and specificity of combined detection of HDAC3 and FOXO1 in predicting the prognosis recurrence of CS patients were 84.38% and 78.41% (P< 0.05). Conclusions: The pattern of dynamic HDAC3 and FOXO1 changes provides a new diagnostic scheme for the development of CI and prognostic recurrence risk in CS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.